Weems H B, Chalecka-Franaszek E, Côté T E
Department of Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814-4799, USA.
J Neurochem. 1996 Mar;66(3):1042-50. doi: 10.1046/j.1471-4159.1996.66031042.x.
High-affinity mu-opioid receptors have been solubilized from rat brain membranes. In most experiments, rats were treated for 14 days with naltrexone to increase the density of opioid receptors in brain membranes. Occupancy of the membrane-associated receptors with morphine during solubilization in the detergent 3-[(3-cholamidopropyl)dimethyl]-1-propane sulfonate appeared to stabilize the mu-opioid receptor. After removal of free morphine by Sephadex G50 chromatography and adjustment of the 3-[(3-cholamidopropyl)dimethyl]-1-propane sulfonate concentration to 3 mM, the solubilized opioid receptor bound [3H][D-Ala2,N-Me-Phe4,Gly-Dl5]-enkephalin([3H]DAMGO), a mu-selective opioid agonist, with high affinity (KD = 1.90 +/- 0.93 nM; Bmax = 629 +/- 162 fmol/mg of protein). Of the membrane-associated [3H]-DAMGO binding sites, 29 +/- 7% were recovered in the solubilized fraction. Specific [3H]DAMGO binding was completely abolished in the presence of 10 microM guanosine 5'-O-(3-thiotriphosphate). The solubilized receptor also bound [3H]diprenorphine, a nonselective opioid antagonist, with high affinity (KD = 1.4 +/- 0.39 nM, Bmax = 920 +/- 154 fmol/mg of protein). Guanosine 5'-O-(3-thiotriphosphate) did not diminish [3H]diprenorphine binding. DAMGO at concentrations between 1 nM and 1 microM competed with [3H]diprenorphine for the solubilized binding sites; in contrast, [D-Pen2, D-Pen5]-enkephalin, a delta-selective opioid agonist, and U50488H, a kappa-selective opioid agonist, failed to compete with [3H]diprenorphine for the solubilized binding sites at concentrations of < 1 microM. In the absence of guanine nucleotides, the DAMGO displacement curve for [3H]diprenorphine binding sites better fit a two-site than a one-site model with KDhigh = 2.17 +/- 1.5 nM, Bmax = 648 +/- 110 fmol/mg of protein and KDlow = 468 +/- 63 nM, Bmax = 253 +/- 84 fmol/mg of protein. In the presence of 10 microM guanosine 5'-O-(3-thiotriphosphate), the DAMGO displacement curve better fit a one- than a two-site model with KD = 815 +/- 33 nM, Bmax = 965 +/- 124 fmol/mg of protein.
高亲和力的μ-阿片受体已从大鼠脑膜中溶解出来。在大多数实验中,大鼠用纳曲酮处理14天,以增加脑膜中阿片受体的密度。在去污剂3-[(3-胆酰胺丙基)二甲基]-1-丙烷磺酸盐中溶解时,用吗啡占据膜相关受体似乎能稳定μ-阿片受体。通过Sephadex G50柱色谱去除游离吗啡并将3-[(3-胆酰胺丙基)二甲基]-1-丙烷磺酸盐浓度调节至3 mM后,溶解的阿片受体与μ-选择性阿片激动剂[3H][D-Ala2,N-Me-Phe4,Gly-Dl5]-脑啡肽([3H]DAMGO)以高亲和力结合(KD = 1.90±0.93 nM;Bmax = 629±162 fmol/mg蛋白质)。在溶解部分中回收了29±7%的膜相关[3H]-DAMGO结合位点。在10μM鸟苷5'-O-(3-硫代三磷酸)存在下,特异性[3H]DAMGO结合完全被消除。溶解的受体也与非选择性阿片拮抗剂[3H]二丙诺啡以高亲和力结合(KD = 1.4±0.39 nM,Bmax = 920±154 fmol/mg蛋白质)。鸟苷5'-O-(3-硫代三磷酸)不降低[3H]二丙诺啡结合。浓度在1 nM至1μM之间的DAMGO与[3H]二丙诺啡竞争溶解的结合位点;相反,δ-选择性阿片激动剂[D-Pen2,D-Pen5]-脑啡肽和κ-选择性阿片激动剂U50488H在浓度<1μM时未能与[3H]二丙诺啡竞争溶解的结合位点。在不存在鸟嘌呤核苷酸的情况下,[3H]二丙诺啡结合位点的DAMGO置换曲线更符合双位点模型而非单位点模型,KDhigh = 2.17±1.5 nM,Bmax = 648±110 fmol/mg蛋白质,KDlow = 468±63 nM,Bmax = 253±84 fmol/mg蛋白质。在10μM鸟苷5'-O-(3-硫代三磷酸)存在下,DAMGO置换曲线更符合单位点模型而非双位点模型,KD = 815±33 nM,Bmax = 965±124 fmol/mg蛋白质。